Axsome Therapeutics (AXSM) News Today $102.89 +1.29 (+1.27%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$103.65 +0.76 (+0.74%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Hunter R. Murdock Sells 7,500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) StockJune 19 at 7:26 AM | insidertrades.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 SharesAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) General Counsel Hunter R. Murdock sold 7,500 shares of Axsome Therapeutics stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total value of $751,950.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.June 18 at 11:21 PM | marketbeat.comProsperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Prosperity Wealth Management Inc. bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,750 shareJune 18 at 5:14 AM | marketbeat.comBrokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $172.33June 17 at 2:25 AM | americanbankingnews.comRBC Capital Remains a Buy on Axsome Therapeutics (AXSM)June 14, 2025 | theglobeandmail.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Buy" by BrokeragesAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has received an average rating of "Buy" from the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy recommendation and one has issued a strong buy recommenJune 14, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by GAMMA Investing LLCGAMMA Investing LLC grew its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 38,571.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,043 shares of the company's stock after purchasing an additional 21,986 shares during thJune 13, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $186.00 at Royal Bank of CanadaJune 13, 2025 | americanbankingnews.comQ3 EPS Forecast for Axsome Therapeutics Lowered by AnalystJune 13, 2025 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $186.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada lowered their target price on Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a report on Thursday.June 12, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)June 12, 2025 | theglobeandmail.comAssenagon Asset Management S.A. Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Assenagon Asset Management S.A. boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 16,852.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 627,418 shares of the compaJune 12, 2025 | marketbeat.comRhumbline Advisers Raises Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Rhumbline Advisers grew its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 6.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,760 shares of the company's stock after purchasJune 12, 2025 | marketbeat.comAxsome Therapeutics (AXSM) Gets a Buy from Piper SandlerJune 12, 2025 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Apellis Pharmaceuticals (APLS) and Bio-Rad Laboratories (BIO)June 12, 2025 | theglobeandmail.comOppenheimer Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)June 11, 2025 | theglobeandmail.comAxsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan StanleyJune 11, 2025 | msn.comWilliam Blair Analysts Reduce Earnings Estimates for AXSMAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at William Blair lowered their Q3 2026 EPS estimates for shares of Axsome Therapeutics in a research note issued on Monday, June 9th. William Blair analyst M. Minter now anticipates that the company will post earnings perJune 11, 2025 | marketbeat.comAxsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025June 11, 2025 | globenewswire.comMark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) StockJune 11, 2025 | insidertrades.comResearch Analysts Set Expectations for AXSM FY2026 EarningsJune 11, 2025 | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Harrow Health (HROW)June 11, 2025 | theglobeandmail.comNeedham & Company LLC Lowers Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00June 11, 2025 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells $2,761,000.00 in StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark L. Jacobson sold 25,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares of the company's stock, valued at approximately $638,674.52. This trade represents a 81.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.June 10, 2025 | marketbeat.comCantor Fitzgerald Predicts AXSM FY2026 EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Axsome Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($0.41) per share forJune 10, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Axsome Therapeutics in a report on Tuesday.June 10, 2025 | marketbeat.comAxsome shares fall after FDA issues Refusal to File letterJune 9, 2025 | investing.comAxsome fell after FDA refuses to review AXS-14 applicationJune 9, 2025 | msn.com2AXSM : Demystifying Axsome Therapeutics: Insights From 11 Analyst ReviewsJune 9, 2025 | benzinga.comAxsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End ProfitabilityJune 9, 2025 | msn.comAxsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLCNeedham & Company LLC decreased their target price on shares of Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating for the company in a research report on Monday.June 9, 2025 | marketbeat.comPallas Capital Advisors LLC Boosts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Pallas Capital Advisors LLC grew its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 33.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,280 shares of the company's stock after buying an additional 8,845 sJune 9, 2025 | marketbeat.comAxsome Therapeutics, Inc.: Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of FibromyalgiaJune 9, 2025 | finanznachrichten.deAxsome Therapeutics Receives Refusal From FDAJune 9, 2025 | marketwatch.comAxsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of FibromyalgiaJune 9, 2025 | financialpost.com2 Soaring Stocks Wth More Upside PotentialJune 5, 2025 | fool.comOppenheimer Initiates Coverage of Axsome Therapeutics (AXSM) with Outperform RecommendationJune 4, 2025 | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,642 shares of the company'sJune 4, 2025 | marketbeat.comTwo Sigma Advisers LP Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Two Sigma Advisers LP grew its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 85.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,300 shares of the company's stock after buying an additional 2,900 sharJune 4, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Now Covered by OppenheimerOppenheimer began coverage on Axsome Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $185.00 price objective on the stock.June 3, 2025 | marketbeat.com111 Capital Takes $278,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)111 Capital purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,291 shares of the company's stock, valued at approximatelJune 1, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 179,697 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Ameriprise Financial Inc. trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 90.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 18,238 shares of the company's stock after selling 179,697 shares during the period. AmeJune 1, 2025 | marketbeat.comMark Coleman Sells 3,750 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) Director Mark Coleman sold 3,750 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director now directly owns 50,387 shares of the company's stock, valued at $5,314,316.89. The trade was a 6.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.May 31, 2025 | marketbeat.comWellington Management Group LLP Has $56.96 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Wellington Management Group LLP trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 9.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 673,157 shares of the cMay 31, 2025 | marketbeat.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 20,000 Shares of StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark L. Jacobson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $103.45, for a total transaction of $2,069,000.00. Following the sale, the chief operating officer now directly owns 5,783 shares of the company's stock, valued at $598,251.35. This represents a 77.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.May 30, 2025 | marketbeat.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 20,673 Shares of StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark L. Jacobson sold 20,673 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $104.66, for a total value of $2,163,636.18. Following the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at $605,248.78. This trade represents a 78.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.May 30, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)May 30, 2025 | theglobeandmail.comZacks Research Issues Optimistic Estimate for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research boosted their Q2 2025 earnings per share estimates for Axsome Therapeutics in a research note issued on Monday, May 26th. Zacks Research analyst R. Department now expects that the company will earn ($1.20) per share for the quMay 30, 2025 | marketbeat.comAxsome Therapeutics to Participate in Upcoming Investor ConferencesMay 29, 2025 | financialpost.comAxsome Therapeutics to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.com Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.430.69▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼1111▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News GMAB News ITCI News RDY News ASND News VTRS News QGEN News MRNA News BPMC News BBIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AXSM Stock Free AXSM Stock Alerts